How many drugs treat Local anesthesia?

Drug Landscape tracks 10 marketed treatments for Local anesthesia (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/local-anesthesia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Local anesthesia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Local anesthesia (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Local anesthesia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Tetracaine Hydrochloride	TETRACAINE	Alcon Labs	Ester Local Anesthetic	Sodium channel protein type 7 subunit alpha	2005-01-01
Chirocain	LEVOBUPIVACAINE	Purdue Pharma Lp	levobupivacaine	Cytochrome P450 2D6	1999-01-01
Naropin	ROPIVACAINE	Fresenius Kabi	Amide Local Anesthetic	Sodium channel protein type 5 subunit alpha	1996-01-01
Versed	midazolam	Generic (originally Roche)	Benzodiazepine (short-acting)	Multidrug resistance protein 1, Cytochrome P450 3A4, GABA A receptor alpha-3/beta-2/gamma-2	1985-12-20
Versed	Midazolam Hydrochloride	Takeda Pharmaceutical Company Limited	Benzodiazepine	GABA A receptor alpha-5/beta-2/gamma-2	1985-01-01
Nembutal Sodium	PENTOBARBITAL	Oak Pharms	pentobarbital	GABA-A receptor alpha-1/beta-2/gamma-2	1973-01-01
Bupivacaine Hydrochloride	Bupivacaine Hydrochloride	Pfizer	Amide-type local anesthetic	Nerve sodium channels	1972-01-01
Bupivacaine Hydrochloride And Epinephrine	BUPIVACAINE	Innocoll	Amide Local Anesthetic	Cytochrome P450 2D6	1972-01-01
Ketalar	ketamine	Ph Health	General Anesthetic	Glutamate [NMDA] receptor	1970-01-01
Duragesic	fentanyl	Johnson & Johnson (Janssen Pharmaceutica)	Synthetic opioid analgesic	D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor	1968-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 12 drugs in Local anesthesia
Pfizer · 4 drugs in Local anesthesia
Fresenius Kabi · 3 drugs in Local anesthesia
Ph Health · 2 drugs in Local anesthesia
Bausch Health · 2 drugs in Local anesthesia
Endo · 1 drug in Local anesthesia
Eastman Kodak · 1 drug in Local anesthesia
Alcon Labs · 1 drug in Local anesthesia
Hadassah Medical Organization · 1 drug in Local anesthesia
Generic (originally Roche) · 1 drug in Local anesthesia
Innocoll · 1 drug in Local anesthesia
Generic (multiple manufacturers) · 1 drug in Local anesthesia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Local anesthesia:

Cite this brief

Drug Landscape (2026). Local anesthesia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/local-anesthesia. Accessed 2026-06-10.

Local anesthesia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing